Veraxa Biotech AG - Post de-SPAC
VRXAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002079109
In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders filed 4 open-market purchases and 0 sales; 27 institutions reported holding it in 13F filings for Q2 2026, worth $992.5K in total; no superinvestor holds it.
Other share classesVRXA
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $125.3K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +27 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $992.5K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.79K
- Shares sold short
- Change
- −3.97K
- −33.8% vs. previous
- Days to cover
- 1.22
- At average daily volume
Superinvestors holding VRXAW, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VRXAW at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Veraxa Biotech AG - Post de-SPAC insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 29, 2026 (view filing)4:52 PM ET | Oct 27-28 | 2 days | Gruninger MarcDirector | PPurchase | +10.0K | $0.9983 | +$9.98K | New position10.0K after | 2 lots |
| Oct 21, 2026 (view filing)4:10 PM ET | Oct 20 | 1 day | Ziegler Christoph SamuelDirector | PPurchase | +30.0K | $1.09 | +$32.7K | +378.2%37.9K after | |
| Aug 31, 2026 (view filing)4:10 PM ET | Aug 27 | 4 days | Baumann Oliver RolfDirector | PPurchase | +50.0K | $1.50 | +$75.0K | +0.9%5.77M after | |
| Aug 31, 2026 (view filing)4:10 PM ET | Aug 27 | 4 days | Antz Christoph RudigerChief Executive Officer | PPurchase | +5.00K | $1.53 | +$7.65K | New position5.00K after |
Top 10 13F holders, Q2 2026
See all 27 holdersThe largest institutional positions in Veraxa Biotech AG - Post de-SPAC at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CSS LLC | 1,600,882 | $176.6K | 0.01% | +1,600,882 | New |
| LMR Partners LLP | 1,089,100 | $120.1K | 0.00% | +1,089,100 | New |
| Magnetar Financial LLC | 1,055,078 | $116.4K | 0.00% | +1,055,078 | New |
| Aristeia Capital LLC | 976,083 | $115.7K | 0.00% | +976,083 | New |
| Alberta Investment Management Corp | 875,000 | $96.5K | 0.00% | +875,000 | New |
| CNH Partners LLC | 658,138 | $72.6K | 0.00% | +658,138 | New |
| Clear Street Group Inc. | 485,358 | $53.5K | 0.00% | +485,358 | New |
| JPMorgan Chase & Co | – | $43.8K | 0.00% | – | New |
| BNP Paribas Arbitrage, SA | 253,207 | $27.9K | 0.00% | +253,207 | New |
| Whitebox Advisors LLC | 193,612 | $21.4K | 0.00% | +193,612 | New |
Holders of 5% or more of VRXAW
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Veraxa Biotech AG - Post de-SPAC.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Deck David Lukas | 13D | 18.00%25.5M shares | New | Jun 16, 20261 filing | Jun 16, 2026 | SEC |
| Xlife Sciences AG | 13D | 16.30%23.0M shares | New | Jun 15, 20261 filing | Jun 15, 2026 | SEC |
| European Molecular Biology Laboratory | 13D | 16.20%22.9M shares | New | Jun 16, 20261 filing | Jun 16, 2026 | SEC |
| Schoeni Gilbert Edgar | 13D | 15.90%22.5M shares | New | Jun 15, 20261 filing | Jun 15, 2026 | SEC |